So-Young, China’s dominant player in the medical aesthetics market, is facing a growing wave of consumer complaints and judicial scrutiny over its lending arm, 'Yang Fen Bei.' While the platform markets itself as a gateway to affordable beauty, recent court documents and investigative reports reveal a predatory financial architecture designed to squeeze high yields from vulnerable borrowers. The discrepancy between public marketing and actual loan terms highlights the persistent 'grey zones' in China’s rapidly evolving consumer credit sector.
Investigations into Yang Fen Bei reveal a triple-tiered interest rate structure that often blindsides consumers. While promotional materials suggest annualized rates as low as 8.4% to 15%, actual contracts frequently hit the 24% regulatory ceiling. For those who fall behind on payments, the financial burden escalates dramatically; penalty rates combined with original interest can effectively soar to over 200% annually. Though courts typically cap these claims at 24% during litigation, many borrowers who do not reach the trial stage end up paying these exorbitant penalties.
The lending operation utilizes a sophisticated 'trust bypass' mechanism to circumvent interest rate caps intended for private lenders. By funneling its own corporate capital through licensed entities like Yunnan International Trust, So-Young has attempted to brand its loans as 'financial institution' products. This distinction is critical in the Chinese legal system, as institutional lenders historically enjoyed higher interest rate protections in court compared to private or peer-to-peer lenders.
However, the judicial tide is turning against such regulatory arbitrage. Recent rulings show that Chinese judges are increasingly applying the 'substance over form' principle, reclassifying these trust-channeled loans as private lending. This shift caps the allowable interest at four times the Loan Prime Rate (LPR)—currently around 14.6%—significantly lower than the 24% So-Young targets. As regulators move to slash overall financing costs across the economy, these high-interest 'beauty loans' are becoming a primary target for enforcement.
Beyond the financial mechanics, the ethical implications of 'beauty loans' (yimeidai) remain a point of intense public debate. Reports indicate that some cosmetic clinics, partnered with So-Young, allegedly lure job seekers into surgeries by promising employment, only to saddle them with debt before the first paycheck arrives. As the medical aesthetics industry matures, the integration of high-interest credit into the patient acquisition funnel is being viewed less as a financial innovation and more as a systemic risk to social stability.